This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Radius Health Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
Anahtar bilgiler
28.6%
Kazanç büyüme oranı
30.1%
EPS büyüme oranı
| Biotechs Sektör Büyümesi | 17.0% |
| Gelir büyüme oranı | 35.3% |
| Özkaynak getirisi | n/a |
| Net Marj | -30.7% |
| Son Kazanç Güncellemesi | 30 Jun 2022 |
Yakın geçmiş performans güncellemeleri
Recent updates
Radius Recycling Stays In The Scrap Pile
Jul 16Radius Recycling: An Attractive, But Volatile, Play On A Cleaner Future
Jun 03Radius stock rises as elacestrant gets FDA priority review to treat breast cancer subtype
Aug 11Reevaluating Radius Health
Feb 24Radius Health EPS misses by $0.02, misses on revenue
May 07When Will Radius Health, Inc. (NASDAQ:RDUS) Become Profitable?
Feb 23
Revisiting Radius Health
Feb 01Radius Health acquires global rights to RAD011 in Prader-Willi syndrome
Jan 06How Much Did Radius Health's(NASDAQ:RDUS) Shareholders Earn From Share Price Movements Over The Last Five Years?
Jan 01
Radius Health on-track for record quarterly revenue for TYMLOS-SC
Dec 15Gelir ve Gider Dağılımı
Gelir ve Gider Dağılımı
Radius Health nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 30 Jun 22 | 223 | -69 | 129 | 121 |
| 31 Mar 22 | 217 | -73 | 127 | 122 |
| 31 Dec 21 | 230 | -70 | 130 | 131 |
| 30 Sep 21 | 228 | -76 | 138 | 128 |
| 30 Jun 21 | 249 | -60 | 134 | 134 |
| 31 Mar 21 | 247 | -87 | 140 | 151 |
| 31 Dec 20 | 239 | -109 | 143 | 159 |
| 30 Sep 20 | 232 | -113 | 144 | 158 |
| 30 Jun 20 | 200 | -136 | 148 | 149 |
| 31 Mar 20 | 191 | -128 | 150 | 131 |
| 31 Dec 19 | 173 | -133 | 155 | 115 |
| 30 Sep 19 | 152 | -149 | 163 | 104 |
| 30 Jun 19 | 133 | -169 | 170 | 100 |
| 31 Mar 19 | 115 | -203 | 179 | 99 |
| 31 Dec 18 | 99 | -221 | 186 | 98 |
| 30 Sep 18 | 72 | -251 | 193 | 97 |
| 30 Jun 18 | 58 | -259 | 197 | 91 |
| 31 Mar 18 | 37 | -259 | 199 | 84 |
| 31 Dec 17 | 22 | -254 | 189 | 81 |
| 30 Sep 17 | 14 | -236 | 167 | 82 |
| 30 Jun 17 | 1 | -224 | 138 | 89 |
| 31 Mar 17 | 0 | -199 | 104 | 97 |
| 31 Dec 16 | 0 | -183 | 80 | 105 |
| 30 Sep 16 | 0 | -163 | 62 | 104 |
| 30 Jun 16 | 0 | -145 | 51 | 95 |
| 31 Mar 16 | 0 | -125 | 40 | 84 |
| 31 Dec 15 | 0 | -102 | 31 | 68 |
Kaliteli Kazançlar: RDUS is currently unprofitable.
Büyüyen Kar Marjı: RDUS is currently unprofitable.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: RDUS is unprofitable, but has reduced losses over the past 5 years at a rate of 28.6% per year.
Büyüme Hızlandırma: Unable to compare RDUS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Kazançlar vs. Sektör: RDUS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (24.5%).
Özkaynak Getirisi
Yüksek ROE: RDUS's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.